Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men.
BACKGROUND
Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer. Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types.


METHODS
AIDS Malignancy Consortium Protocol 052 is a single-arm, open-label, multicenter clinical trial to assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HIV-1-infected men. Men with high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded. Men received 0.5 mL intramuscularly at entry, week 8, and week 24. The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination.


RESULTS
There were no grade 3 or greater adverse events attributable to vaccination among the 109 men who received at least 1 vaccine dose. Seroconversion was observed for all 4 types: type 6 (59 [98%] of 60), type 11 (67 [99%] of 68), type 16 (62 [100%] of 62), and type 18 (74 [95%] of 78). No adverse effects on CD4 counts and plasma HIV-1 RNA levels were observed.


CONCLUSIONS
The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1-infected men. Efficacy studies in HIV-1-infected men are warranted. Clinical trials registration. NCT 00513526.
Wilkin
Timothy
T
Division of Infectious Diseases, Weill Cornell Medical College, Montefiore Medical Center, New York, New York, USA. tiw2001@med.cornell.edu
Lee
Jeannette Y
JY
Lensing
Shelly Y
SY
Stier
Elizabeth A
EA
Goldstone
Stephen E
SE
Berry
J Michael
JM
Jay
Naomi
N
Aboulafia
David
D
Cohn
David L
DL
Einstein
Mark H
MH
Saah
Alfred
A
Mitsuyasu
Ronald T
RT
Palefsky
Joel M
JM
D000328:Adult; D001003:Anal Canal / Q000166:cytology / Q000473:pathology / Q000821:virology; D000914:Antibodies, Viral / Q000097:blood; D001005:Anus Neoplasms / Q000473:pathology / Q000821:virology; D015658:HIV Infections; D015497:HIV-1; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D008297:Male; D008875:Middle Aged; D053918:Papillomavirus Vaccines / Q000276:immunology* / Q000592:standards*
D000914:Antibodies, Viral; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines
N Engl J Med. 2007 May 10;356(19):1928-43
17494926
Int J Cancer. 2009 May 15;124(10):2375-83
19189402
J Infect Dis. 1997 Sep;176(3):625-31
9291307
AIDS. 2008 Jun 19;22(10):1203-11
18525266
Clin Infect Dis. 2005 Oct 1;41(7):1045-8
16142673
BMC Infect Dis. 2003 Apr 30;3:6
12723991
Clin Infect Dis. 2002 Nov 1;35(9):1127-34
12384848
Am J Obstet Gynecol. 1984 Aug 15;149(8):815-23
6205589
N Engl J Med. 2007 May 10;356(19):1915-27
17494925
Vaccine. 2006 Jan 16;24(3):272-9
16139398
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9
18614927
Sex Transm Dis. 2005 May;32(5):314-20
15849533
Lancet. 1998 Jun 20;351(9119):1833-9
9652666
Dis Colon Rectum. 1997 Aug;40(8):919-28
9269808
Am J Pathol. 1992 Jun;140(6):1345-55
1318640
J Infect Dis. 1998 Feb;177(2):361-7
9466522
J Clin Microbiol. 1992 Oct;30(10):2539-43
1328278
Ann Intern Med. 2008 May 20;148(10):728-36
18490686
J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5
15577408
Clin Diagn Lab Immunol. 2005 Aug;12(8):959-69
16085914
Clin Diagn Lab Immunol. 2003 Jan;10(1):108-15
12522048
Lancet. 2009 Jun 6;373(9679):1949-57
19493565
Int J STD AIDS. 2009 Sep;20(9):595-600
19710329